الفهرس 
Creatine kinase isoformsOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Acute coronary syndromes are currently one of the
leading causes of death in industrialized countries & are
expected to become so in emerging countries by 2020.
Management of patients presented with ST elevation
myocardial infarction is rapid reperfusion either by primary
PCI or firinolysis while patients presented with non ST
acute coronary syndromes varies according to the risk
stratification of the patients from conservative
management, early invasive & very early invasive strategy
The aim of the study was to assess the usefulness of
using heart-type fatty acid binding protein (H-FABP) as an
early diagnostic biochemical marker for NSTEMI in
patients with NSTE-ACS in comparison to Troponin and as
regard sensitivity, specificity and time of early detection.
This is for proper and optimal management.
The study included 61 patients who presented to ER
by typical chest pain within the first 4 hours from its onset.
The population in the study underwent detailed
history taking, clinical examination and ECG monitoring.
All patients had normal kidney functions tests. Blood
samples for H-FABP and Troponin and were obtained on
admission for patients presenting to ED within the first 4
hours of onset of chest pain.Patients with negative Troponin test in first set, had a
second set assessment after 6 hours.
Sensitivity and specificity of HFABP was calculated
in detection of myocardial ischemia and necrosis to all
population included in the study in comparison to
Troponin.
Our study showed sensitivity of 89.36% for FABP, It
showed also specificity of 100 % FABP.
We conclude that qualitative assessment of H-FABP
showed good sensitivity and specificity in early detection
and diagnosis of NSTEMI cases from all patients presented
with NSTE-ACS, and this provided early management for
them.
We recommend that H-FABP assessment is better to
be combined with cardiac Troponin assessment which is
more specific, to confirm or exclude the diagnosis of
NSTEMI.